Hemostatic effect of activated factor VII without promotion of thrombus growth in melagatran-anticoagulated primates

Thrombosis Research

Volumn 119, Issue 1, 2007, Pages 121-127

  Gruber, András ^a   Carlsson, Stefan ^b   Kotzé, Harry F ^c   Marzec, Ulla ^a   Sarich, Troy C ^d   Hanson, Stephen R ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b ASTRAZENECA R AND D   (Sweden)

^c NORTH WEST UNIVERSITY   (South Africa)

^d ASTRAZENECA   (United Kingdom)

Author keywords

Anticoagulation; Bleeding; Hemostasis; Thrombosis; Tissue factor

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 7A INHIBITOR; MELAGATRAN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN;

ANIMAL EXPERIMENT; ANTICOAGULATION; ARTERIOVENOUS SHUNT; ARTERY; ARTICLE; BABOON; BLEEDING TIME; BLOOD VESSEL GRAFT; CONTROLLED STUDY; DRUG INFUSION; DRUG MEGADOSE; FIBRIN DEPOSITION; HEMOSTASIS; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STATISTICAL ANALYSIS; THROMBOCYTE AGGLUTINATION; THROMBOGENESIS;

ANIMALS; ANTICOAGULANTS; AZETIDINES; BENZYLAMINES; CASE-CONTROL STUDIES; FACTOR VIIA; HEMOSTASIS; HUMANS; MALE; PAPIO; PROTEIN C; RECOMBINANT PROTEINS; THROMBOSIS; TIME FACTORS;

EID: 33751275469     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2005.12.002     Document Type: Article

References (38)

1. Levine M.N., Raskob G., Beyth R.J., Kearon C., and Schulman S. Hemorrhagic complications of anticoagulant treatment: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126 Suppl 3 (2004) 287S-310S
2. Connolly S.J. Preventing stroke in patients with atrial fibrillation: current treatments and new concepts. Am Heart J 145 (2003) 418-423
3. Haverkamp D., Hutten B.A., Buller H.R., Gallus A.S., Lensing A.W., and Prins M.H. The use of specific antidotes as a response to bleeding complications during anticoagulant therapy for venous thromboembolism. J Thromb Haemost 1 (2003) 69-73
4. Bijsterveld N.R., Moons A.H., Boekholdt S.M., van Aken B.E., Fennema H., Peters R.J., et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 106 (2002) 2550-2554
5. Elg M., Carlsson S., and Gustafsson D. Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthaetised rats and rabbits. Thromb Res 101 (2001) 159-170
6. Elg M., Carlsson S., and Gustafsson D. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. Thromb Res 101 (2001) 145-157
7. Scharrer I. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency. Haemophilia 5 (1999) 253-259
8. Shapiro A.D., Gilchrist G.S., Hoots W.K., Cooper H.A., and Gastineau D.A. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 80 (1998) 773-778
9. Lusher J.M., Shapiro S.S., Palascak J.E., Rao A.V., Levine P.H., and Blatt P.M. Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial. N Engl J Med 303 (1980) 421-425
10. Sjamsoedin L.J., Heijnen L., Mauser-Bunschoten E.P., van Geijlswijk J.L., van Houwelingen H., van Asten P., et al. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. N Engl J Med 305 (1981) 717-721
11. Negrier C., Goudemand J., Sultan Y., Bertrand M., Rothschild C., and Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA study group. Factor eight bypassing activity. Thromb Haemost 77 (1997) 1113-1119
12. Turecek P.L., Varadi K., Gritsch H., Auer W., Pichler L., Eder G., et al. Factor Xa and prothrombin: mechanism of action of FEIBA. Vox Sang 77 Suppl 1 (1999) 72-79
13. Akhavan S., Mannucci P.M., Lak M., Mancuso G., Mazzucconi M.G., Rocino A., et al. Identification and three-dimensional structural analysis of nine novel mutations in patients with prothrombin deficiency. Thromb Haemost 84 (2000) 989-997
14. Xi M., Beguin S., and Hemker H.C. The relative importance of the factors II, VII, IX and X for the prothrombinase activity in plasma of orally anticoagulated patients. Thromb Haemost 62 (1989) 788-791
15. Kohler M., Hellstern P., Lechler E., Uberfuhr P., and Muller-Berghaus G. Thromboembolic complications associated with the use of prothrombin complex and factor IX concentrates. Thromb Haemost 80 (1998) 399-402
16. Hoffman M., and Monroe III D.M. A cell-based model of hemostasis. Thromb Haemost 85 (2001) 958-965
17. Lee A., Agnelli G., Buller H., Ginsberg J., Heit J., Rote W., et al. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation 104 (2001) 74-78
18. Buddai S.K., Toulokhonova L., Bergum P.W., Vlasuk G.P., and Krishnaswamy S. Nematode anticoagulant protein c2 reveals a site on factor Xa that is important for macromolecular substrate binding to human prothrombinase. J Biol Chem 277 (2002) 26689-26698
19. Badimon J.J., Lettino M., Toschi V., Fuster V., Berrozpe M., Chesebro J.H., et al. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation 99 (1999) 1780-1787
20. Soderstrom T., Hedner U., and Arnljots B. Active site-inactivated factor VIIa prevents thrombosis without increased surgical bleeding: topical and intravenous administration in a rat model of deep arterial injury. J Vasc Surg 33 (2001) 1072-1079
21. Taylor F.B., Chang A.C., Peer G., Li A., Ezban M., and Hedner U. Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8 but not tumor necrosis factor responses of the baboon to LD100 Escherichia coli. Blood 91 (1998) 1609-1615
22. Sorensen B.B., Hedner U., and Erhardtsen E. rFVIIai in acute coronary syndromes. Semin Vasc Med 3 (2003) 199-204
23. Kirchhofer D., Tschopp T.B., and Baumgartner H.R. Active site-blocked factors VIIa and IXa differentially inhibit fibrin formation in a human ex vivo thrombosis model. Arterioscler Thromb Vasc Biol 15 (1995) 1098-1106
24. Ghrib F., Leger P., Ezban M., Kristensen A., Cambus J., and Boneu B. Anti-thrombotic and haemorrhagic effects of active site-inhibited factor VIIa in rats. Br J Haematol 112 (2001) 506-512
25. Himber J., Wohlgensinger C., Roux S., Damico L.A., Fallon J.T., Kirchhofer D., et al. Inhibition of tissue factor limits the growth of venous thrombus in the rabbit. J Thromb Haemost 1 (2003) 889-895
26. Sambola A., Osende J., Hathcock J., Degen M., Nemerson Y., Fuster V., et al. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation 107 (2003) 973-977
27. Bogdanov V.Y., Balasubramanian V., Hathcock J., Vele O., Lieb M., and Nemerson Y. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 9 (2003) 458-462
28. Butenas S., and Mann K.G. Active tissue factor in blood?. Nat Med 10 (2004) 1155-1156
29. Gruber A., and Hanson S.R. Factor XI-dependence of surface- and tissue factor-initiated thrombus propagation in primates. Blood 102 (2003) 953-955
30. Gustafsson D., Nystrom J., Carlsson S., Bredberg U., Eriksson U., Gyzander E., et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 101 (2001) 171-181
31. Eriksson U.G., Bredberg U., Gislen K., Johansson L.C., Frison L., Ahnoff M., et al. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur J Clin Pharmacol 59 (2003) 35-43
32. Halperin J.L. Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation. J Am Coll Cardiol 45 (2005) 1-9
33. Hanson S.R., Griffin J.H., Harker L.A., Kelly A.B., Esmon C.T., and Gruber A. Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates. J Clin Invest 92 (1993) 2003-2012
34. Hanson S.R., and Harker L.A. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin d-phenylalanyl-l-prolyl-l-arginyl chloromethyl ketone. Proc Natl Acad Sci U S A 85 (1988) 3184-3188
35. Hanson S.R., Kotze H.F., Savage B., and Harker L.A. Platelet interactions with Dacron vascular grafts. A model of acute thrombosis in baboons. Arteriosclerosis 5 (1985) 595-603
36. Larsson M., Ahnoff M., Abrahamsson A., Logren U., Fakt C., Ohrman I., et al. Determination of ximelagatran, an oral direct thrombin inhibitor, its active metabolite melagatran, and the intermediate metabolites, in biological samples by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 783 (2003) 335-347
37. Eriksson B.I., Agnelli G., Cohen A.T., Dahl O.E., Mouret P., Rosencher N., et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost 89 (2003) 288-296
38. Cullberg M., Eriksson U.G., Wåhlander K., Eriksson H., Schulman S., and Karlsson M.O. Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis. Clin Pharmacol Ther 77 (2005) 279-290